CY2011010I2 - Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους - Google Patents

Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Info

Publication number
CY2011010I2
CY2011010I2 CY2011010C CY2011010C CY2011010I2 CY 2011010 I2 CY2011010 I2 CY 2011010I2 CY 2011010 C CY2011010 C CY 2011010C CY 2011010 C CY2011010 C CY 2011010C CY 2011010 I2 CY2011010 I2 CY 2011010I2
Authority
CY
Cyprus
Prior art keywords
preparation
methods
macrocyclic analogs
macrocyclic
analogs
Prior art date
Application number
CY2011010C
Other languages
English (en)
Other versions
CY2011010I1 (el
Original Assignee
Eisai R&D Management Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2011010(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd filed Critical Eisai R&D Management Co., Ltd
Publication of CY2011010I1 publication Critical patent/CY2011010I1/el
Publication of CY2011010I2 publication Critical patent/CY2011010I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CY2011010C 1998-06-17 2011-08-12 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους CY2011010I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (2)

Publication Number Publication Date
CY2011010I1 CY2011010I1 (el) 2014-04-09
CY2011010I2 true CY2011010I2 (el) 2014-04-09

Family

ID=22219026

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100530T CY1111516T1 (el) 1998-06-17 2011-06-01 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους
CY2011010C CY2011010I2 (el) 1998-06-17 2011-08-12 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20111100530T CY1111516T1 (el) 1998-06-17 2011-06-01 Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους

Country Status (22)

Country Link
US (4) US6214865B1 (el)
EP (4) EP2272840B1 (el)
JP (1) JP4454151B2 (el)
KR (1) KR100798600B1 (el)
CN (1) CN1216051C (el)
AT (1) ATE502932T1 (el)
AU (1) AU762998B2 (el)
BE (1) BE2011C028I2 (el)
BR (1) BRPI9911326B8 (el)
CA (3) CA2335300C (el)
CY (2) CY1111516T1 (el)
DE (2) DE69943296D1 (el)
DK (1) DK1087960T3 (el)
FR (1) FR11C0038I2 (el)
HU (1) HU227912B1 (el)
IL (1) IL139960A0 (el)
LU (1) LU91854I2 (el)
NO (5) NO328280B1 (el)
NZ (1) NZ508597A (el)
PT (1) PT1087960E (el)
WO (1) WO1999065894A1 (el)
ZA (1) ZA200007159B (el)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP2272840B1 (en) * 1998-06-17 2012-08-22 Eisai R&D Management Co., Ltd. Intermediate compound for the preparation of halichondrin analogs
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
MXPA04009209A (es) 2002-03-22 2004-11-26 Eisai Co Ltd Derivados de hemiasterlina y usos de los mismos.
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
EP1644008B1 (en) * 2003-05-29 2011-12-21 Abbott Laboratories Continuous dosing regimen with abt-751
WO2005011589A2 (en) * 2003-07-29 2005-02-10 Eisai Co., Ltd. Drug delivery methods and devices
KR101434673B1 (ko) * 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 ｂ 유사체의 제조를 위한 중간체
CN1993342A (zh) * 2004-06-03 2007-07-04 卫材株式会社 用于制备软海绵素b的中间体
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
US20060154312A1 (en) * 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
US8598373B2 (en) * 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
AU2010232347A1 (en) 2009-03-30 2011-09-29 Eisai R&D Management Co., Ltd. Liposome composition
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
JP5556811B2 (ja) * 2009-04-14 2014-07-23 日産化学工業株式会社 テトラヒドロピラン化合物の製造方法
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体
WO2012129100A1 (en) 2011-03-18 2012-09-27 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN104053645A (zh) 2011-11-30 2014-09-17 阿方拉研究股份有限公司 用于制备(3r)-2,4-二-离去基团-3-甲基丁-1-烯的工艺
WO2013086634A1 (en) 2011-12-16 2013-06-20 Alphora Research Inc. Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
WO2013097042A1 (en) * 2011-12-29 2013-07-04 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
IN2014MN02106A (el) * 2012-03-30 2015-09-11 Alphora Res Inc
AU2013353745A1 (en) 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
CA2909209A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
RU2672585C2 (ru) 2013-06-26 2018-11-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
AU2014286880B2 (en) * 2013-07-03 2017-12-14 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
BR112016009452B1 (pt) 2013-11-04 2022-06-07 Eisai R&D Management Co., Ltd Métodos de preparar intermediários na síntese de eribulina, métodos de preparar eribulina e mesilato de eribulina, e compostos intermediários
SG10201805024YA (en) 2013-12-06 2018-07-30 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) * 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
BR112016026545A8 (pt) * 2014-05-28 2021-07-06 Eisai R&D Man Co Ltd eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
EP3191479B1 (en) * 2014-09-09 2020-04-08 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
ES2967362T3 (es) 2015-02-25 2024-04-29 Eisai R&D Man Co Ltd Método para suprimir el amargor de un derivado de quinolina
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
CN107849057B (zh) 2015-05-07 2020-11-10 卫材R&D管理有限公司 用于合成软海绵素大环内酯的大环化反应及中间体和其他片段
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
KR20180107243A (ko) * 2016-02-12 2018-10-01 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린의 합성에서의 중간체 및 관련된 합성 방법
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
JP2019521969A (ja) * 2016-05-26 2019-08-08 ドクター レディズ ラボラトリーズ リミテッド エリブリン及びその中間体の製造方法
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
US20190263927A1 (en) 2016-10-14 2019-08-29 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
KR20190084065A (ko) * 2016-11-23 2019-07-15 닥터 레디스 레보러터리즈 리미티드 에리불린 및 그 중간체의 제조방법
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
JP6920699B2 (ja) * 2017-01-02 2021-08-18 ヨンスン ファイン ケミカル カンパニー，リミテッド エリブリンメシル酸塩の製造中間体及びその製造方法
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
AU2018219637B2 (en) 2017-02-08 2023-07-13 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
PT3606928T (pt) 2017-04-05 2022-12-05 Harvard College Composto macrocíclico e utilizações deste
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
MX2020000142A (es) 2017-07-06 2020-07-22 Harvard College Sintesis de halicondrinas.
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
CN111328328B (zh) * 2017-11-09 2023-05-23 研成精密化学株式会社 用于制备甲磺酸艾日布林的中间体及其制备方法
EP4403560A3 (en) 2017-11-15 2024-10-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019102490A1 (en) 2017-11-21 2019-05-31 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
WO2019136145A1 (en) 2018-01-03 2019-07-11 Eisai R&D Management Co., Ltd. Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
US20210260023A1 (en) * 2018-07-20 2021-08-26 Dr. Reddy's Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
WO2020132636A1 (en) 2018-12-20 2020-06-25 Auransa Inc. Analogues of pentamidine and uses therefor
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2020255164A1 (en) 2019-06-21 2020-12-24 Council Of Scientific And Industrial Research A chemo-enzymatic process for the preparation of homopropargylic alcohol
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
PH12022551036A1 (en) 2019-11-07 2023-05-29 Eisai R&D Man Co Ltd Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
US20230144203A1 (en) * 2020-01-22 2023-05-11 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
US20240382607A1 (en) * 2021-07-22 2024-11-21 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
AU2024209545A1 (en) * 2023-01-17 2025-08-07 Systimmune, Inc. Conjugate of eribulin drug
WO2025081063A2 (en) 2023-10-13 2025-04-17 Eisai R&D Management Co., Ltd. Antibody-drug conjugate metabolites
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP2272840B1 (en) * 1998-06-17 2012-08-22 Eisai R&D Management Co., Ltd. Intermediate compound for the preparation of halichondrin analogs
KR101434673B1 (ko) 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 ｂ 유사체의 제조를 위한 중간체
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
JP5134686B2 (ja) 2007-11-16 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂアナログ合成のための新規な中間体及び前記中間体に用いるための新規な脱スルホニル化反応
US8598373B2 (en) 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体

Also Published As

Publication number Publication date
NO20006316L (no) 2001-02-15
US6365759B1 (en) 2002-04-02
BE2011C028I2 (en) 2018-08-24
PT1087960E (pt) 2011-06-17
EP1087960B1 (en) 2011-03-23
BR9911326A (pt) 2001-04-03
EP1087960A4 (en) 2004-12-01
US6469182B1 (en) 2002-10-22
NO2011026I1 (no) 2012-01-09
CY2011010I1 (el) 2014-04-09
AU4573999A (en) 2000-01-05
RU2245335C2 (ru) 2005-01-27
CA2632433C (en) 2012-02-07
AU762998B2 (en) 2003-07-10
NO2011026I2 (no) 2012-06-11
DE69943296D1 (de) 2011-05-05
EP2272839A1 (en) 2011-01-12
CA2755266A1 (en) 1999-12-23
LU91854I2 (fr) 2011-10-17
DE122011100031I1 (de) 2011-12-15
NO20006316D0 (no) 2000-12-12
NO20093217L (no) 2001-02-15
JP4454151B2 (ja) 2010-04-21
ZA200007159B (en) 2001-12-04
EP1087960A1 (en) 2001-04-04
NO2022019I1 (no) 2022-06-03
EP2277873B1 (en) 2012-05-30
HU227912B1 (en) 2012-05-29
FR11C0038I2 (fr) 2013-01-11
CN1216051C (zh) 2005-08-24
CN1312804A (zh) 2001-09-12
ATE502932T1 (de) 2011-04-15
WO1999065894A1 (en) 1999-12-23
US8148554B2 (en) 2012-04-03
HUP0103357A3 (en) 2002-10-28
CY1111516T1 (el) 2014-04-09
KR100798600B1 (ko) 2008-01-28
KR20010083050A (ko) 2001-08-31
EP2272840A1 (en) 2011-01-12
CA2335300C (en) 2008-10-07
DK1087960T3 (da) 2011-06-14
EP2277873A1 (en) 2011-01-26
FR11C0038I1 (fr) 2011-10-14
BRPI9911326B8 (pt) 2021-05-25
JP2002518384A (ja) 2002-06-25
NO331183B1 (no) 2011-10-24
EP2272840B1 (en) 2012-08-22
US6214865B1 (en) 2001-04-10
NZ508597A (en) 2004-01-30
NO328280B1 (no) 2010-01-25
EP2272839B1 (en) 2012-08-22
US20110172446A1 (en) 2011-07-14
CA2335300A1 (en) 1999-12-23
BR9911326B1 (pt) 2015-01-06
AU762998C (en) 2000-01-05
CA2632433A1 (en) 1999-12-23
HUP0103357A2 (hu) 2002-01-28
NO2011018I1 (no) 2011-09-26
IL139960A0 (en) 2002-02-10
CA2755266C (en) 2014-08-12
HK1035534A1 (en) 2001-11-30

Similar Documents

Publication Publication Date Title
CY2011010I1 (el) Μακροκυκλικα αναλογα και μεθοδοι χρησης και παρασκευης τους
CY2016006I1 (el) Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους
DE69505657D1 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
DE69831755D1 (de) Optoakustische kontrastmittel und anwendungsverfahren
ID23338A (id) Popok tarik sekali pakai
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
IS2325B (is) Örgerðar samsetningar epleróns
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
PT1100459E (pt) Preparacao oleosa espumante e sua utilizacao
EE200000155A (et) Taksoidide klassi kuuluvate derivaatide valmistamismeetod
PT934057E (pt) Formulacoes medicinais de aerossois com formoterol
FR2744442B1 (fr) Preparation du 1,1,1,3,3-pentachlorobutane et du 1,1,1,3,3,-pentafluorobutane
ID23198A (id) Popok tarik sekali pakai
FI972245A7 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
BR9707501A (pt) Composto composição farmacêutica e uso do composto
LV12624A (lv) Thienylazolylalcoxyethanamines their preparation and their application as medicaments
ID18679A (id) Penggunaan terapi lanjutan
MX9205721A (es) Metodo de uso y composiciones de win 49596-finasteride
DE69934889D1 (de) Herstellung und reinigung von diboranen
NO20012011D0 (no) Fremstilling og anvendelse av stivnede oljer
FI964936L (fi) Bentsopyraaneja ja niiden käyttö terapeuttisina aineina
NO20010654L (no) Ny anvendelse av taxoidderivater
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
PT1084126E (pt) Novos derivados de vinca-alcaloides e processos de preparacao
ITMI912290A1 (it) Miscele di n-alchilftalimmidi, loro preparazione e loro impiego